BSTC out with a strong q: EPS of .15 vs .10 a year ago (fully diluted) Revenue up 26% PDUFA September 6 for Peyronie's Disease Multiple catalysts in the 2nd half of 2013 Low float and AUXL footing the bills finance.yahoo.com/news/biospecifics-technologies-corp-reports-second-113000459.html